These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 18653375)

  • 1. Vascular endothelial growth factor in eye disease.
    Penn JS; Madan A; Caldwell RB; Bartoli M; Caldwell RW; Hartnett ME
    Prog Retin Eye Res; 2008 Jul; 27(4):331-71. PubMed ID: 18653375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].
    Fan SJ; He SZ
    Zhonghua Yan Ke Za Zhi; 2011 Apr; 47(4):373-7. PubMed ID: 21612688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of vascular endothelial growth factor in ocular angiogenesis.
    Shams N; Ianchulev T
    Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases.
    Li Y; Zhou Y
    Tohoku J Exp Med; 2019 Feb; 247(2):87-98. PubMed ID: 30773517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factors and angiogenesis in eye disease.
    Witmer AN; Vrensen GF; Van Noorden CJ; Schlingemann RO
    Prog Retin Eye Res; 2003 Jan; 22(1):1-29. PubMed ID: 12597922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin.
    Smith RO; Ninchoji T; Gordon E; André H; Dejana E; Vestweber D; Kvanta A; Claesson-Welsh L
    Elife; 2020 Apr; 9():. PubMed ID: 32312382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration?
    Saravia M; Zeman L; Ingolotti M; Schlaen A
    Med Hypotheses; 2017 Nov; 109():156-161. PubMed ID: 29150277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
    Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Liou GI; Caldwell RW
    Curr Drug Targets; 2005 Jun; 6(4):511-24. PubMed ID: 16026270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
    Le YZ
    Vision Res; 2017 Oct; 139():108-114. PubMed ID: 28601428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
    Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW
    Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.
    Muniyandi A; Hartman GD; Song Y; Mijit M; Kelley MR; Corson TW
    J Pharmacol Exp Ther; 2023 Jul; 386(1):15-25. PubMed ID: 37142441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization.
    Tolentino MJ
    Curr Mol Med; 2009 Nov; 9(8):973-81. PubMed ID: 19925410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for the treatment of ocular neovascularization.
    Bradley J; Ju M; Robinson GS
    Angiogenesis; 2007; 10(2):141-8. PubMed ID: 17372853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic retinopathy and angiogenesis.
    Crawford TN; Alfaro DV; Kerrison JB; Jablon EP
    Curr Diabetes Rev; 2009 Feb; 5(1):8-13. PubMed ID: 19199892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF Inhibition Therapy in Ocular Diseases.
    Lee D; Miwa Y; Kunimi H; Ibuki M; Shoda C; Nakai A; Kurihara T
    Keio J Med; 2022 Mar; 71(1):1-12. PubMed ID: 33840673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
    Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
    Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema.
    Fogli S; Mogavero S; Egan CG; Del Re M; Danesi R
    Pharmacol Res; 2016 Jan; 103():149-57. PubMed ID: 26607863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.